Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711346 | 0.90 | MEN1 (0.44) | CES2CES1RECQLALDH1A1 | |
| SCHEMBL6712717 | 0.90 | ALDH1A1 (0.40) | MAPK14CES2CES1POLBALDH1A1 | |
| SCHEMBL29898841 | 0.88 | DGAT1 (0.43) | ALDH1A1 | |
| SCHEMBL933685 | 0.88 | DGAT1 (0.43) | ALDH1A1 | |
| SCHEMBL6710179 | 0.88 | ALDH1A1 (0.44) | CES2CES1POLBALDH1A1 | |
| SCHEMBL6712769 | 0.87 | MEN1 (0.38) | RECQL | |
| SCHEMBL6712739 | 0.87 | ALDH1A1 (0.40) | CES2CES1POLBALDH1A1 | |
| SCHEMBL26982329 | 0.85 | PDE2A (0.42) | — | |
| SCHEMBL6709920 | 0.82 | MAPK14 (0.40) | MAPK14CES2CES1 | |
| SCHEMBL27241238 | 0.81 | MRGPRX1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2024-06-13 | — | — | US | disclosed |
| EP-4301745-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | King's College London (GB) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022185055-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2022-09-09 | — | — | WO | disclosed |
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | disclosed |
| EP-0898566-B1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL NV (NL) | 2002-11-06 | — | — | EP | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| EP-0898566-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | Akzo Nobel N.V. (NL) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040027-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL N.V. (NL) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | HCN2, HCN1, HCN3 | MAPK14 728/4885CES2 2511/4885CES1 3070/4885 |
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | MAPK14 2893/4885CES2 353/4885CES1 3442/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | MAPK14 2893/4885CES2 353/4885CES1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.